Differences

This shows you the differences between two versions of the page.

--- braden_manns [2022/07/09 20:34]
liam created
+++ braden_manns [2025/01/09 00:42] (current)
liam
@@ Line 27: / Line 27: @@
 ==== Alberta Kidney Disease Network ====
-Manns was a member of the [[:Alberta Kidney Disease Network]], funded by an unrestricted grant from [[:Amgen]].((//Our Team.// (2017, October 23). Alberta Kidney Disease Network. https://web.archive.org/web/20171023095419/https://www.akdn.info/our-team))
+Manns was a member of the [[:Alberta Kidney Disease Network]], which was initially funded by an unrestricted grant from [[pharmaceutical_companies:Amgen]].((//Our Team.// (2017, October 23). Alberta Kidney Disease Network. https://web.archive.org/web/20171023095419/https://www.akdn.info/our-team)) ((Hemmelgarn, B. R., Clement, F., Manns, B. J., Klarenbach, S., James, M. T., Ravani, P., Pannu, N., Ahmed, S. B., MacRae, J., Scott-Douglas, N., Jindal, K., Quinn, R., Culleton, B. F., Wiebe, N., Krause, R., Thorlacius, L., & Tonelli, M. (2009). //Overview of the Alberta Kidney Disease Network.// BMC Nephrology, 10(1). https://doi.org/10.1186/1471-2369-10-30))
 ==== Alberta SPOR Unit ====
@@ Line 46: / Line 46: @@
 ==== Canadian Society of Nephrology ====
-Manns served as President of the [[:Canadian Society of Nephrology]], funded by [[:Alexion]], [[:Amgen]], [[:AstraZeneca]], [[:Bayer]], [[:Boehringer Ingelheim]], [[:Eli Lilly]], [[:Fresenius]], [[:Horizon Therapeutics]], [[:Janssen]], and [[:Otsuka]].((//Our Partners.// CSN/SCN. Retrieved January 8, 2022, from https://archive.ph/Omio2)) ((//HE Braden Manns.// O’Brien Institute for Public Health. Retrieved January 8, 2022, from https://obrieniph.ucalgary.ca/research/centres-programs-research-groups-and-units/health-economics/meet-our-team/dr-braden-manns-0))
+Manns served as President of the [[Canadian Society of Nephrology]], funded by [[pharmaceutical_companies:Alexion]], [[pharmaceutical_companies:Amgen]], [[pharmaceutical_companies:AstraZeneca]], [[pharmaceutical_companies:Bayer]], [[pharmaceutical_companies:Boehringer Ingelheim]], [[pharmaceutical_companies:Eli Lilly]], [[pharmaceutical_companies:Fresenius]], [[pharmaceutical_companies:GlaxoSmithKline]], [[pharmaceutical_companies:Horizon Therapeutics]], [[pharmaceutical_companies:Janssen]], [[pharmaceutical_companies:Otsuka]] and [[pharmaceutical_companies:Pfizer]].((//Our Partners.// CSN/SCN. Retrieved January 8, 2022, from https://archive.ph/Omio2)) ((//HE Braden Manns.// O’Brien Institute for Public Health. Retrieved January 8, 2022, from https://obrieniph.ucalgary.ca/research/centres-programs-research-groups-and-units/health-economics/meet-our-team/dr-braden-manns-0)) ((//Our Partners.// Canadian Society of Nephrology. Retrieved October 22, 2022, from https://web.archive.org/web/20221022180917/https://www.csnscn.ca/our-partners/))
 ==== Kidney Foundation of Canada ====
@@ Line 65: / Line 64: @@
 === Interdisciplinary Chronic Disease Collaboration ===
-He also served as co-lead for the University's Interdisciplinary Chronic Disease Collaboration, which was funded by Alberta Innovates (which is partnered with [[:pharmaceutical_companies:Pfizer]].((Brunner, D. (2018, November 26). //Alberta Government and Pfizer Canada boosts provincial collaborative health innovation partnership with Alberta Innovates.// Alberta Innovates. https://archive.ph/1ppaw))
+He also served as co-lead for the University's Interdisciplinary Chronic Disease Collaboration, which was funded by Alberta Innovates (which is partnered with [[:pharmaceutical_companies:Pfizer]]).((Brunner, D. (2018, November 26). //Alberta Government and Pfizer Canada boosts provincial collaborative health innovation partnership with Alberta Innovates.// Alberta Innovates. https://archive.ph/1ppaw))
 ===== Funding =====
@@ Line 82: / Line 81: @@
 ==== Pharmaceutical Companies ====
-Manns has received funding via an unrestricted grant from [[:Baxter]].((Trachtenberg, A. J., Quinn, A. E., Ma, Z., Klarenbach, S., Hemmelgarn, B., Tonelli, M., Faris, P., Weaver, R., Au, F., Zhang, J., & Manns, B. (2020). //Association between change in physician remuneration and use of peritoneal dialysis: a population-based cohort analysis.// CMAJ Open, 8(1), E96–E104. https://doi.org/10.9778/cmajo.20190132))
+Manns has received funding via an unrestricted grant from [[pharmaceutical_companies:Baxter]].((Trachtenberg, A. J., Quinn, A. E., Ma, Z., Klarenbach, S., Hemmelgarn, B., Tonelli, M., Faris, P., Weaver, R., Au, F., Zhang, J., & Manns, B. (2020). //Association between change in physician remuneration and use of peritoneal dialysis: a population-based cohort analysis.// CMAJ Open, 8(1), E96–E104. https://doi.org/10.9778/cmajo.20190132))
 ===== Media Appearances =====
@@ Line 89: / Line 88: @@
   * [[https://www.campfire.wiki/lib/exe/fetch.php?media=public_health_agencies:canada:scn_podcast_-_december_2021.mp3|SCN Podcast - December 2021]]((AHS Communications. (2021, December). //SCN Podcast - December 2021.// SoundCloud. https://soundcloud.com/ahs-communications/scn-podcast-december-2021))
+===== External links =====
+  * [[https://www.whiteroseintelligence.com/braden-manns/|White Rose Wiki]]